Correction by unknown
CORRECTION The Journal of Cell Biology
Murphy-Ullrich et al., Vol . 115, No. 4, 1127-1136. Due to an author's error, the following information
on the mAbs was omitted from the paper.
mAb 81C6 has been characterized previously as binding
to human tenascin (1, 2, 4) . This antibody, and the U-251
MG-(clone 3) cell line used to produce human tenascin,
were generously provided by Dr. D. D. Bigner (Department
of Pathology, Duke University Medical Center). mAb 127
has previously been studied and shown to bind to an epitope
in the alternatively spliced region of human and chicken
tenascin (3).
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